Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims to investigate the impact of preeclampsia on hemostasis.
In comparison to healthy pregnant women and non-pregnant woman, this study analyses parameters of primary hemostasis and plasmatic coaguation in preeclamptic pregnant woman. Detailed analyses of the platelet function is performed using the Multiple Electrode Aggregometry, detailed analyses of the plasmatic coagulation syste is performed by isolated coaguation factor analyses and conventional coagulation analyses.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pregnant Preeclampsia | Pregnant between 35th and 40th week of pregnancy Preeclampisa Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling |
| |
| Pregnant No-Preeclampsia | Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling |
| |
| Not Pregnant | Control group 2 Healthy and not pregnant control group Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aggregometry, Monitoring of plasmatic hemostasis | Diagnostic Test | Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count) |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry | ADP induced platelet aggregation | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the aggregation curve in the ASPItest of the Multiple Electrode Aggregometry | Arachidonic acid induced platelet aggregation | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study |
| Area under the aggregation curve in the TRAPtest of the Multiple Electrode Aggregometry |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Female (Study cohort is pregnant, control group should be female too)
Pregnant patients suffering from preeclampsia, n = 20
Control group 1: Healthy pregnant patients, not suffering from preeclampsia, n=20
Control group 2: Healthy woman (age between 18 and 40y) that are not pregnant
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christian F Weber, MD, PhD | Contact | +49 69 6301 5514 | christian.weber@kgu.de | |
| Niels Loechelt, MD | Contact | +49 69 6301 5514 | niels.loechelt@kgu.de |
| Name | Affiliation | Role |
|---|---|---|
| Christian F Weber, MD, PhD | Goethe University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001778 | Blood Coagulation Disorders |
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Thrombin induced platelet aggregation |
| Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study |
| Parameters of plasmatic coagulation system | von Willebrand Factor, Factor VIII, Factor XIII, parameter of conventional coagulation testing (apTT, INR, platelet count, Fibrinogen) | Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study |